Scientific Sessions 2025  /  Obesity: Refining Definitions and Clinical Approaches  /  Optimizing the medical approach to your patient with obesity
Logo

American Heart Association

  37
  0

Final ID:

Optimizing the medical approach to your patient with obesity

  • Jastreboff, Ania  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Stanford, Fatima  ( Massachusetts General Hospital , Boston , Massachusetts , United States )
  • Lingvay, Ildiko  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Kahan, Scott  ( JOHNS HOPKINS UNIV , Manalapan , New Jersey , United States )
  • Gudzune, Kimberly  ( The American Board of Obesity Medicine Foundation , Baltimore , Maryland , United States )
    • Author Disclosures:
    Ania Jastreboff: No Answer | Fatima Stanford: DO NOT have relevant financial relationships | Ildiko Lingvay: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Betagenon:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Alveus Therapeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Lilly:Active (exists now) ; Research Funding (PI or named investigator):Dexcom:Active (exists now) | Scott Kahan: DO have relevant financial relationships ; Consultant:Novo Nordisk:Active (exists now) ; Consultant:Viking Therapeutics:Active (exists now) ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Currax:Active (exists now) ; Consultant:Lilly:Active (exists now) | Kimberly Gudzune: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Advisor:Eli Lilly:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Obesity: Refining Definitions and Clinical Approaches

Sunday, 11/09/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Redefining obesity: highlights from The Lancet Diabetes & Endocrinology Commission

Rubino Francesco, Eckel Robert

Perspective from The Obesity Society: remaining challenges in defining and addressing obesity

Ard Jamy, Kaplan Lee

More abstracts from these authors:
Debate 1: Early incretin therapy for long term brain health: Get started already! - No, the data is not there yet

Jastreboff Ania, Lingvay Ildiko, Marso Steven, Goldenberg Ronald

How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

You have to be authorized to contact abstract author. Please, Login
Not Available